Clover Health Corp (NASDAQ: CLOV) experienced a significant after-hours surge of 5.12% following the release of its fourth quarter and full-year 2025 financial results.

The company reported quarterly sales of $487.7 million, surpassing analyst estimates of $467.1 million and representing a 44.7% increase compared to the same period last year. While the quarterly loss per share of $0.10 was in line with expectations, the strong revenue performance and forward-looking guidance appear to have driven investor optimism.

Key highlights from the report include full-year 2025 revenue growth of 40.3% to $1.9 billion and a 38% increase in Medicare Advantage membership. Most notably, management provided full-year 2026 guidance projecting total revenues between $2.81 billion and $2.92 billion and, importantly, anticipating its first full year of GAAP net income profitability. The company cited improving cohort economics driven by its Clover Assistant platform and strong membership growth, including a 53% year-over-year increase in Annual Enrollment Period growth.